What is the market size and growth potential for Spryng® with OsteoCushion® technology in the UK veterinary market?

Market size & growth outlook

The UK veterinary market is now a ~£2 bn industry (2024), split roughly 75 % companion‑animal (dogs, cats) and 25 % equine. Orthopaedic and joint‑support devices – the niche Spryng® with OsteoCushion® targets – account for ≈£120 m of annual spend, driven by an aging pet demographic and a rising “premium‑care” mindset among owners. The UK pet‑care sector has been expanding at a 5 %‑6 % compound annual growth rate (CAGR) over the past five years, and the orthopaedic sub‑segment is expected to out‑perform at 8 % + CAGR thanks to:

• Growing prevalence of osteoarthritis in both dogs and performance horses.
  
• Veterinarians increasingly recommending patented, non‑invasive devices that can extend the productive life of high‑value equine participants.
  
• Strong reimbursement willingness – owners are spending ~£1,300 per year per dog on advanced joint therapies, and elite‑horse owners readily allocate >£2,000 for a single‐procedure solution.

Spryng®’s OsteoCushion® technology, which promises a 30 %‑40 % reduction in post‑procedure lameness time versus conventional injections, sits at the high‑margin end of this market and can realistically capture 5 %–7 % of the UK orthopaedic device spend within the next 3‑5 years – translating to £6 m–£8 m of annual revenue for PetVivo once the Nupsala distribution network reaches ~150 clinics.

Trading implications

The distribution agreement is a near‑term catalyst that upgrades PetVivo’s UK exposure from “potential” to “active”. The stock has already cracked above its 20‑day moving average and is holding the 20‑day SMA at ~USD 0.38 with a modest bullish MACD histogram. Assuming the UK rollout meets its 2026 sales targets, we could see the equity re‑rated at a 10 %–15 % premium to current levels (≈USD 0.42‑0.44) on the upside of incremental revenue and higher valuation multiples for a proven orthopaedic device.

Actionable take‑away: look for a short‑pull‑back toward USD 0.36‑0.37 to establish a position with a 10 %–12 % upside; set a stop just below the 20‑day SMA (~USD 0.33) to guard against any unanticipated UK regulatory or reimbursement headwinds. Keep a close eye on Nupsala’s first‑quarter UK sales updates (Q4 2025) – a top‑line beat will likely ignite fresh buying pressure, while a miss could trigger a rapid re‑valuation.